365213-69-0

Usage

Uses

Used in Pharmaceutical Industry:
(2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID is used as a drug candidate for the development of new medications targeting neurological and psychiatric disorders. Its potential pharmacological properties make it a promising candidate for further research and development in the field of medicine.
Used in Research and Development:
In the scientific community, (2-P-TOLYL-IMIDAZO[1,2-A]PYRIDIN-3-YL)-ACETIC ACID is used as a subject of study to explore its potential pharmacological properties and mechanisms of action. This research aims to better understand the compound's therapeutic potential and to identify its possible applications in the treatment of various medical conditions.

Upstream product

• 365213-61-2 2-(2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide 
• 65964-60-5 2-para-tolylimidazo[1,2-a]pyridine 
• 365213-41-8 N,N-dimethyl-1-(2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)methanamine 
• 122-00-9 para-methylacetophenone 
• 124658-44-2 C₁₃H₁₄O₃ 
• 504-29-0 2-aminopyridine 
• 16208-14-3 2,2-dihydroxy-1-(p-tolyl)ethanone 

Relevant academic research and scientific papers

Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3)

STAT3 has been validated as an attractive anticancer target due to its important roles in cancer initiation and progression. However, discovery of potent and selective STAT3 small-molecule inhibitors with druglike properties is still challenging. In this study, two series of substituted 2-phenylquinolines and 2-arylimidazo[1,2-a]pyridines were designed through structure-based drug discovery approach by condensing the privileged structures of STX-119 and SH4-54. Our study has resulted in the discovery of a number of highly potent and selective STAT3 inhibitors, exemplified by compound 39 with the privileged structure of 2-phenylimidazo[1,2-a]pyridine, which selectively inhibits phosphorylation of STAT3 and suppresses subsequent signaling pathway. Moreover, 39 inhibits cell growth, migration and invasion of human triple negative breast cancer (TNBC) cells lines. Consistently, it achieves significant and dose-dependent tumor growth inhibition in both cell line-derived and patient-derived xenograft tumor models in mice. These results clearly indicate that 39 is a highly potent and selective STAT3 inhibitor.

Imidazopyridine compound, pharmaceutical composition containing the same, and preparation method and application thereof (by machine translation)

Specifically discloses a pharmaceutical composition containing the compound and a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate [1,2 - a] of the compound, and the preparation method, comprises the following steps of inhibiting, protein selectivity, drug effect strong STAT3 patent medicine, safety and the like, and the like . is particularly suitable for preventing and, or treating tumor growth and metastasis as well as pharmaceutical composition and pharmaceutical acceptable salt or pharmaceutically acceptable salt or pharmaceutically acceptable solvate of the compound in preparing STAT3 high-expression cell abnormal proliferation, form change and exercise function hyperthyroidism, and other related diseases / and are disclosed in the present invention. (by machine translation)

Synthesis of Substituted Imidazo[1,2-a]Pyridin-3-yl-Acetic Acids by Multicomponent Condensation of 2-Aminopyridines with Arylglyoxals and Meldrum’s Acid

[Figure not available: see fulltext.] A simple and effective method for the synthesis of substituted imidazo[1,2-a]pyridin-3-yl-acetic acids has been developed based on the multicomponent condensation of 2-aminopyridines with arylglyoxals and Meldrum's acid.

Flow chemistry synthesis of zolpidem, alpidem and other GABAA agonists and their biological evaluation through the use of in-line frontal affinity chromatography

The flow of information between chemical and biological research can present a bottleneck in pharmaceutical research. Tools that bridge these disciplines and aid information exchange have therefore clear value. Over the last few years, both synthetic chemistry and biological screening have benefited from automation, and a seamless chemistry-biology interface is now possible. We report here on the use of flow processes to perform synthesis and biological evaluation in an integrated manner. As proof of concept, a flow synthesis of a series of imidazo[1,2-a]pyridines, including zolpidem and alpidem, was developed and connected to a Frontal Affinity Chromatography screening assay to investigate their interaction with Human Serum Albumin (HSA). The Royal Society of Chemistry 2013.

A structure-activity relationship study of the affinity of selected imidazo[1,2-a]pyridine derivatives, congeners of zolpidem, for the ω1-subtype of the benzodiazepine receptor

A series of 6-substituted 2-aryl-N,N-dimethylimidazol [1,2-a]pyridine-3-acetamides, congeners of zolpidem and alpidem, was synthesized and tested in vitro for binding with the benzodiazepine receptor in the competition with 3H-zolpidem as an ω1-selective radioligand. Molecular electrostatic potential (MEP) and the HOMO and LUMO energies were calculated for the compounds by semi-empirical quantum chemistry methods. The lipophilicity parameter of the compounds, expressed as the logarithm of the octanol-water partition coefficient (log P), was calculated; alternatively, standard values of the Hansch hydrophobic substituent constants π were used. In agreement with earlier investigations on the benzodiazepine receptor ligands with a high preference for the ω1-subtype, a quantitative correlation of the biological data with molecular parameters has revealed a significant dependence (r=0.954) of the binding affinity (IC50) on the deepest MEP minimum, in this case associated with the amide carbonyl oxygen atom. The lipophilicity parameters were found to be of lower significance.